Replies to post #246831 on Avid Bioservices Inc (CDMO)

[itsabouttime]

U.S. Bancorp Piper Jaffray dropping coverage was a big green flag.
Several prominent investors are positioning to invest.

[Protector]

biopharm, I like this post. Apart from what all the trued(s) are of what happened with PPHM's stock, clinical trials sabotages and organized eMagazine and Twitter actions to hinder the company, it emphasises that more then normal things have been happening.

And in my experience when more then normal things happen and they become so obvious and actually consistent in nature then this is always because of MONEY.

The results of 1st and 2nd ln NSCLC, Pancreatic and possibly with hindsight HCV all suffering from a defect the makes the trial results worthless, or if failed could have made it worthless, is TO MUCH for one company.

What the roles are of BMY, Ayer, Piper Jaffray's but also AF, PC, West, Schwartz, Finken, Bleecker, etc in all that we may possibly never know. But one thing we do know, coincidence or not, is that if it WASN'T orchestrated then at least it sounded like a well rehearsed requiem.

But this "Missa pro Defunctis" was a little premature and resulted in the resurrection of PPHM, in better shape then it has ever been in its complete existance :)

[north40000]

Just a short flight to/from Fargo:

Minneapolis (headquarters)
800 Nicollet Mall
Suite 1000
Minneapolis, MN 55402

http://www.piperjaffray.com/2col.aspx?id=134

But there is too much attention being paid to the news from Fidelity site the last few days, IMO. It makes me think half the people here have post-Christmas syndrome. People, including analysts, move on to other locations.

[md1225]

Odd article reads today. Someone is nervous imo.

Over 100 reads on:

http://seekingalpha.com/article/2953756-wall-streets-current-play-immunotherapy-of-cancer

Only 12 reads on "Art of the Deal"

No more naked shorting.

Chris LaCoursiere

[biopharm]

...Piper Jaffray would withhold its research on the company unless it was permitted to underwrite its secondary stock offerings.
..

Will we ever know the real reason why Piper Jaffray dropped coverage of Peregrine Pharmaceuticals? Maybe not.... but after reading the above post in full one MUST question their motives, especially since Immunotherapy is going to help Billions upon Billions.

I think Piper Jaffray should be ashamed after seeing this video:

Thank You Piper Jaffray for not helping Peregrine Pharmaceuticals and on biopharms blacklist ...I think its amazing that some here know more than some biotech analysts.

Next, if Peregrine comes up with some additional financing sometime over the next 14 trading days, then maybe Piper Jaffray withholding coverage of PPHM can be scrutinized even more so....

Analyst Coverage
Firm Analyst

NOBLE Life Science Partners Rahul Jasuja, Ph.D.
FBR & Co. Thomas Yip
ROTH Capital Partners Joseph Pantginis, Ph.D.

http://ir.peregrineinc.com/analysts.cfm